Traws Pharma stock tumbles after UK regulator delays flu trial

Traws Pharma stock is currently tumbling following a decision by a UK regulator to delay the company's flu trial. This regulatory setback has led to a decline in share value as investors react to the news. The market volatility is directly linked to the postponed trial, which has created negative pressure on the stock price. The company is now facing financial repercussions due to the unexpected delay in its clinical development process.